Analyst Rating And TargetAytu BioPharma, Inc. (AYTU) stock is rated as a 'Buy' with a price target of $8.00, indicating confidence in the ADHD franchise's potential to grow and drive profitability.
Clinical Trial AdvancementAntibe Therapeutics Inc. (ATE.TO) received a 'Buy' rating with anticipation for the initiation of a Phase 2 abdominoplasty study and the market's need for novel oral post-operative pain products.
Product SynergyExpecting Combination of Hemopurifier With Santersus Devices to Yield Positive Results; Combination represents a potential cancer treatment option.